AIM ImmunoTech & AstraZeneca's Ampligen-Imfinzi Combo Shows Promising Data in Pancreatic Cancer Trial (DURIPANC)

The landscape of medical innovation is constantly evolving, with dedicated researchers and pharmaceutical companies striving to tackle some of the most challenging diseases known to humankind. One such formidable adversary is pancreatic cancer, a condition often dubbed a "silent killer" due to its aggressive nature and typically late diagnosis.